StockpollyBeta
Get App
Popularity #849
VERA · NASDAQ · Biotechnology

Vera Therapeutics (VERA)

Sells TRUTAKNA and develops immune-mediated kidney disease treatments.

$36.00
After hours−0.22 (−0.61%)
At close$36.22(+5.75%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Cost of revenue0−1−1000010−100
Gross profit0110000−10100
22283237504957808495125112
Research & development162225294033415856608660
6678916162227353952
Selling & marketing0−1−1000106000
General & administrative6688916152222353952
Other expenses000000000100
Operating income−22−27−31−37−50−49−57−80−84−94−125−112
213435644343
Interest income2245577661965
Interest expense112222222622
Other non-operating income−3−1−5−6−5−7−7−5−6−9−6−5
Income before tax−20−26−28−34−47−43−52−77−80−91−121−109
Income tax expense000000000000
Net income from continuing operations−20−26−28−34−47−43−52−77−80−91−121−109
Net income−20−26−28−34−47−43−52−77−80−91−121−109
EPS, basic−$0.45−$0.58−$0.56−$0.62−$0.85−$0.85−$0.81−$1.20−$1.26−$1.39−$1.69−$1.52
EPS, diluted−$0.45−$0.58−$0.56−$0.62−$0.85−$0.85−$0.81−$1.20−$1.26−$1.39−$1.69−$1.52
Weighted average shares, basic444451555555646464647172
Weighted average shares, diluted444451555555646464647172
EBITDA−19−27−26−30−45−41−50−74−78−85−119−107
Depreciation & amortization0−10100010000
EBIT−19−27−26−32−45−42−50−75−78−85−119−108